[1S06e] 15. Advanced Cell and Cell Culture Engineering for Biopharmaceuticals and Functional Food - Part 3

5:00 PM - 5:30 PM JST(8:00 AM - 8:30 AM UTC)

[1ACCE-12-KL] Chimeric Antigen Receptor (CAR) T Cells and Bispecific Protein Engager (BiPE)-Armed T Cells (BATs) for Cancer Immunotherapy

○Mutita Junking^1,2 (1. Division of Molecular Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University (Thailand), 2. Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE-CIT), Faculty of Medicine Siriraj Hospital Mahidol University (Thailand))

Keywords:

Cellular immunotherpy,Chimeric antigen receptor (CAR) T cells,Bi-specific protein engager-armed T (BAT) cells

Adoptive T cell-based immunotherapy has shown remarkable success in hematologic malignancies but remains challenging in solid tumors due to antigen heterogeneity, limited T cell persistence, and an immunosuppressive tumor microenvironment. To address these limitations, we have developed advanced engineering platforms for chimeric antigen receptor (CAR) T cells and bispecific protein engager (BiPE)-armed T cells (BATs). Fourth- and fifth-generation CAR T cell technologies incorporate enhanced co-stimulatory signaling and cytokine modulation to improve T cell activation, persistence, and resistance to exhaustion. These engineered CAR T cells demonstrate improved cytotoxicity and infiltration, particularly in three-dimensional tumor models that better recapitulate the solid tumor microenvironment.In parallel, BATs represent a flexible and modular platform for redirecting T cell specificity. By arming T cells with BiPEs that simultaneously target tumor-associated antigens and CD3 on T cells, BATs enable rapid and antigen-specific cytotoxic responses without permanent genetic modification. Dual-engager strategies that combine tumor targeting with co-stimulatory signaling further enhance T cell function and help overcome antigen escape. Collectively, these complementary approaches provide a versatile framework for next-generation cancer immunotherapy. Their integration with advances in cell and cell culture engineering supports scalable manufacturing and highlights their potential for translational development in biopharmaceutical applications